AMGEN and Repatha at ACC
Indications Important Safety Information Prescribing Information Medical Information
RETURN TO ACC HOME
Connect
With a Rep

Repatha® informational resources

FOURIER subanalysis: Cardiovascular (CV) outcomes data

Examine the evidence for using Repatha® + statin in patients with recent MI (≤12 months). This resource details the results of a FOURIER study subanalysis exploring Repatha® + statin use in patients who've suffered a recent MI compared to those with a more distant MI.

See additional Repatha® data Download now
Evidence for initiating Repatha® in-hospital during the acute phase of ACS

Review the data from the EVOPACS and EVACS trials, including the effects of Repatha® + statin on LDL-C when initiated in-hospital during the acute phase of ACS.

See additional Repatha® data Download now
Maria’s patient profile

Examine a hypothetical NSTEMI patient profile and the evidence for adding Repatha® to a statin.

See patient testimonials Download now
Tony’s patient profile

Examine a hypothetical STEMI patient profile and the evidence for adding Repatha® to a statin.

See patient testimonials Download now
Repatha® Access Specialists (RAS) can help with access

Dedicated RAS can help with coverage for and access to Repatha® when you or your patients have questions.

View in-depth details Download now
Repatha® coverage

Learn about coverage and access for your patients who have commercial, Medicare, and Medicaid insurance. See how the copay card can help your commercially insured patients.

View more details on coverage Download now

ACS = acute coronary syndrome; CV = cardiovascular; LDL-C = low-density lipoprotein cholesterol; MI = myocardial infarction; NSTEMI = non–ST-segment–elevation myocardial infarction; STEMI = ST-elevation myocardial infarction.

IMPORTANT SAFETY INFORMATION
  • Contraindication: Repatha® is contraindicated in patients with a history of a serious hypersensitivity reaction to evolocumab or any of the excipients in Repatha®. Serious hypersensitivity reactions including angioedema have occurred in patients treated with Repatha®.
  • Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, have been reported in patients treated with Repatha®. If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with Repatha®, treat according to the standard of care, and monitor until signs and symptoms resolve.

Please click red ^ to view additional Important Safety Information.

Please see full Prescribing Information.